


What is claimed is:

1. A compound according to Formula (1):

5



(1)

wherein:

- 10 Y represents  $-\text{C}(\text{O})-$  or a covalent bond;

R represents a substituted arylene, a substituted heteroarylene or a covalent bond;

Z represents  $-\text{CH}_2-$ ,  $-\text{NR}_3-$ ,  $-\text{O}-$ ,  $-\text{C}(\text{O})\text{NR}_3-$ ,  $-\text{NR}_3\text{C}(\text{O})-$  or  $-\text{CH}=\text{CH}-$  when R is a substituted arylene or a substituted heteroarylene, and represents  $-\text{CH}_2-$  or  $-\text{CH}=\text{CH}-$  when R is a covalent bond;  $\text{R}_3$  is hydrogen,  $\text{C}_{1-3}$  substituted alkyl, and  $(\text{CH}_2)_{0-2}-\text{C}_{3-6}$  substituted carbocycle;

15

$\text{R}_1$  is selected from the group consisting of:

hydrogen,  $\text{C}_{1-3}$  substituted alkyl,  $\text{C}_{2-3}$  substituted alkenyl,  $\text{C}_{2-3}$  substituted alkynyl, and  $(\text{CH}_2)_{0-2}-\text{C}_{3-6}$  substituted carbocycle;

m is equal to 0 when  $\text{Z} = -\text{NR}_3-$  or  $-\text{CH}_2-$ ; or m is equal to 0 or 1 when  $\text{Z} = -\text{O}-$ ,  $-\text{C}(\text{O})\text{NR}_3-$  or  $-\text{NR}_3\text{C}(\text{O})-$ ; or m is an integer between 0 and 6 when  $\text{Z} = -\text{CH}=\text{CH}-$ ;

20


n is an integer equal to or greater than 2, appropriately chosen so that the number of atoms in the macrocyclic ring ranges from 13 to 16;

or a salt, solvate, or physiologically functional derivative thereof.

25

2. A compound according to claim 1, wherein  $\text{R}_1$  represents hydrogen;

3. A compound according to claim 2, with the following absolute configuration:



or a salt, solvate or physiologically functional derivative thereof.

5

4. A compound according to claim 3 selected from the group consisting of:

N-{[(5R)-16-(Dimethylamino)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

10 N-{[(5R)-16-(4-Morpholinyl)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-(Cyclopropylamino)-4-oxo-2,3,15,17,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

15

N-{[(5R)-16-(4-Morpholinyl)-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-16-Methyl-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1(18),14,16-trien-5-yl]methyl}-N-hydroxyformamide;

20

N-{[(5R)-4-Oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

N-{[(5R)-15-Methyl-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

25

N-{[(5R)-15-(4-Morpholinyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;

- N-{[(5R)-15-(2-Furanyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-  
 1(17),13,15-trien-5-yl]methyl}-N-hydroxyformamide;  
 N-{[(5R)-15-(4-Morpholinyl)-4-oxo-2,3,14,16,17-  
 pentaazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-  
 5 hydroxyformamide;  
 N-{[(5R)-15-(Dimethylamino)-4-oxo-2,3,14,16,17-  
 pentaazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-5-yl]methyl}-N-  
 hydroxyformamide;  
 N-{[(5R)-4-Oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-  
 10 5-yl]methyl}-N-hydroxyformamide;  
 N-{[(5R)-14-Methyl-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-  
 1(16),12,14-trien-5-yl]methyl}-N-hydroxyformamide;  
 N-{[(5R)-14-(Dimethylamino)-4-oxo-2,3,15,16-  
 tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-  
 15 hydroxyformamide;  
 N-{[(5R)-14-(4-Morpholinyl)-4-oxo-2,3,15,16-  
 tetraazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-5-yl]methyl}-N-  
 hydroxyformamide; and  
 N-{[(4R)-3,15-Dioxo-1,2-diazacyclopentadecan-4-yl]methyl}-N-  
 20 hydroxyformamide.

5. A method of treating a bacterial infection by administering to a subject in need of treatment a compound according to claim 1.